Elixir Pharmaceuticals said its partner Siena Biotech has begun the Phase I clinical trial of its inhibitor for the treatment of Huntington’s Disease.
Its first-in-class SIRT1 (sirtuin-1) inhibitor is in a Phase 1a combined single and multiple ascending and multiple ascending dose study in the EU to assess safety, tolerability and pharmacokinetics in healthy volunteers.
Elixir CSP Peter DiStefano said it is a major accomplishment for the company and its partner firm.
“This represents the first sirtuin inhibitor to enter clinical trials and validates the work of our drug discovery and design programme focused on the sirtuin family of enzymes, specifically, our selective SIRT1 inhibitor programme,” DiStefano said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData